Martin Shkreli faces another lawsuit, this time from insurer, alleging plans to create a monopoly for Daraprim

Max Gelman

Senior Editor

The notorious “Pharma Bro” Martin Shkreli prompted national outrage in 2015 when he and then-Turing Pharmaceuticals raised the price of Daraprim, the “gold standard” treatment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Martin Shkreli faces another lawsuit, this time from insurer, alleging plans to create a monopoly for Daraprim

Max Gelman

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

Stem cell startup spun out of George Church’s lab raises $75M

Breaking down silos with a new quantitative approach to drug development

Mar­tin Shkre­li faces an­oth­er law­suit, this time from in­sur­er, al­leg­ing plans to cre­ate a mo­nop­oly for Dara­prim

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Martin Shkreli faces another lawsuit, this time from insurer, alleging plans to create a monopoly for Daraprim